Andy Hsieh
Stock Analyst at William Blair
(4.25)
# 1,429
Out of 4,581 analysts
335
Total ratings
46.6%
Success rate
9%
Average return
Main Sectors:
Stocks Rated by Andy Hsieh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNYA Tenaya Therapeutics | Maintained: Buy | n/a | $0.7366 | - | 5 | Jul 29, 2026 | |
| ALT Altimmune | Reiterated: Hold | n/a | $3.00 | - | 11 | Jul 28, 2026 | |
| AVIR Atea Pharmaceuticals | Maintained: Buy | n/a | $4.55 | - | 10 | Jul 28, 2026 | |
| VKTX Viking Therapeutics | Reiterated: Buy | n/a | $33.27 | - | 38 | Jul 16, 2026 | |
| KLRA Kailera Therapeutics | Maintained: Buy | n/a | $16.89 | - | 4 | Jul 7, 2026 | |
| PYXS Pyxis Oncology | Reiterated: Hold | n/a | $3.02 | - | 10 | Jun 30, 2026 | |
| LNTH Lantheus Holdings | Maintained: Buy | n/a | $100.17 | - | 16 | Jun 27, 2026 | |
| EXEL Exelixis | Reiterated: Buy | n/a | $55.98 | - | 58 | Jun 22, 2026 | |
| GPCR Structure Therapeutics | Reiterated: Buy | n/a | $47.35 | - | 10 | Jun 8, 2026 | |
| CRDF Cardiff Oncology | Reiterated: Buy | n/a | $0.8043 | - | 17 | Jun 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $9.05 | - | 15 | Jun 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $5.90 | - | 5 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $6.93 | - | 27 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $0.6319 | - | 17 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $21.60 | - | 12 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $69.42 | - | 30 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $45.02 | - | 3 | Mar 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $0.5697 | - | 9 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.8369 | n/a | 15 | Dec 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $1.16 | n/a | 22 | Dec 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $134.42 | n/a | 1 | Feb 12, 2019 |
Tenaya Therapeutics
Jul 29, 2026
Maintained: Buy
Price Target: n/a
Current: $0.7366
Upside: -
Altimmune
Jul 28, 2026
Reiterated: Hold
Price Target: n/a
Current: $3.00
Upside: -
Atea Pharmaceuticals
Jul 28, 2026
Maintained: Buy
Price Target: n/a
Current: $4.55
Upside: -
Viking Therapeutics
Jul 16, 2026
Reiterated: Buy
Price Target: n/a
Current: $33.27
Upside: -
Kailera Therapeutics
Jul 7, 2026
Maintained: Buy
Price Target: n/a
Current: $16.89
Upside: -
Pyxis Oncology
Jun 30, 2026
Reiterated: Hold
Price Target: n/a
Current: $3.02
Upside: -
Lantheus Holdings
Jun 27, 2026
Maintained: Buy
Price Target: n/a
Current: $100.17
Upside: -
Exelixis
Jun 22, 2026
Reiterated: Buy
Price Target: n/a
Current: $55.98
Upside: -
Structure Therapeutics
Jun 8, 2026
Reiterated: Buy
Price Target: n/a
Current: $47.35
Upside: -
Cardiff Oncology
Jun 3, 2026
Reiterated: Buy
Price Target: n/a
Current: $0.8043
Upside: -
Jun 1, 2026
Maintained: Buy
Price Target: n/a
Current: $9.05
Upside: -
May 15, 2026
Reiterated: Buy
Price Target: n/a
Current: $5.90
Upside: -
May 12, 2026
Reiterated: Hold
Price Target: n/a
Current: $6.93
Upside: -
May 12, 2026
Reiterated: Buy
Price Target: n/a
Current: $0.6319
Upside: -
May 11, 2026
Reiterated: Hold
Price Target: n/a
Current: $21.60
Upside: -
May 7, 2026
Reiterated: Buy
Price Target: n/a
Current: $69.42
Upside: -
Mar 6, 2026
Downgraded: Hold
Price Target: n/a
Current: $45.02
Upside: -
Aug 7, 2025
Reiterated: Buy
Price Target: n/a
Current: $0.5697
Upside: -
Dec 22, 2023
Rated: Hold
Price Target: n/a
Current: $0.8369
Upside: n/a
Dec 1, 2021
Downgraded: Hold
Price Target: n/a
Current: $1.16
Upside: n/a
Feb 12, 2019
Maintained: Buy
Price Target: n/a
Current: $134.42
Upside: n/a